Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Agensys logo — Pioneering advanced treatments for cancer with innovative th...

Agensys

Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates.

Founded 1997 Series D Total: $106.40M Biotechnology, Health Care +1

General Information

Company Name Agensys
Founded Year 1997
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Agensys. To contact Agensys, visit agensys.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Agensys compare?

A PDF of Agensys and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Agensys soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Agensys

Agensys is a pioneering biotechnology company focusing on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates aimed at treating cancer. Established in 1997 and formerly known as UroGenesys, the company is headquartered in Santa Monica, California. Agensys has gained traction in the biotechnology and pharmaceutical industries, targeting various tumors, including prostate, pancreatic, and bladder cancers. In July 2007, the company secured a significant $41.30M Series D investment led by HBM Healthcare Investments, Jafco Ventures, Alta Partners, OrbiMed, Nextech Invest, Bear Stearns, Tekla Capital Management, Innovis Investments, Lombard Odier, and Duquesne Capital Management. Agensys has been a subsidiary of Astellas Pharma US, Inc. since December 18, 2007. The company's slogan reflects its core mission of innovating advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates.

Business keywords: cancer treatment, therapeutic antibodies, monoclonal antibodies, drug conjugates, oncology research, tumor targeting, prostate cancer, pancreatic cancer, bladder cancer, Santa Monica, Astellas Pharma, biopharmaceutical, innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $41.30M 10
HBM Healthcare Investments Jafco Ventures Alta Partners
HBM Healthcare Investments, Jafco Ventures +8
12 Jul 2007
Debt Financing $3.00M -
05 Mar 2003
Series C $42.80M -
04 Mar 2002
Series B $11.30M -
11 Oct 1999
Series A $8.00M -
10 Nov 1997

Agensys Alternatives & Competitors

View All Alternatives
Agensys vs
Applied Immune Technologies
Applied Immune Technologies

Pioneering innovative therapeutic solutions with specialized antibodies for cancer, viral, and autoi...

Venture round
51-200 employees
Biotechnology, Health Care
Agensys vs
A&G Pharmaceutical, Inc.
A&G Pharmaceutical, Inc. United States

Pioneering the future of cancer treatment and diagnostics through innovative monoclonal antibody dev...

Venture round
8 employees
Biotechnology, Health and Wellness
Agensys vs
Farcast Biosciences
Farcast Biosciences India

24,000 human tumors and counting - building the most precise functional precision tumor microdynamic...

Pre-Seed
38 employees
Biotechnology, Health Care
View all alternatives

FAQ About Agensys

Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates.
Agensys was founded in 1997.
Agensys operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on cancer treatment, therapeutic antibodies, monoclonal antibodies and drug conjugates.
Agensys has completed 5 funding rounds, raising a total of $106.40M. The latest funding stage is Series D.
Top alternatives and competitors to Agensys include Applied Immune Technologies, A&G Pharmaceutical, Inc., Farcast Biosciences, Oncomatryx Biopharma, ImmunoBiochem Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Agensys and Applied Immune Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Agensys, https://bouncewatch.com/company/agensys, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes